Efficacy and safety of endostar combined with chemoradiotherapy versus chemoradiotherapy alone in locally advanced cervical cancer: A PRISMA-compliant systematic review and meta-analysis.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
09 Sep 2022
09 Sep 2022
Historique:
entrez:
10
9
2022
pubmed:
11
9
2022
medline:
14
9
2022
Statut:
ppublish
Résumé
To evaluate the role and safety of endostar in cervical cancer by comparing the efficacy and adverse reactions of endostar combined with concurrent chemoradiotherapy in patients with locally advanced cervical carcinoma. The quality of the included literature was evaluated by searching the database for the comparison of endostar combined with concurrent radiotherapy and chemotherapy in cervical cancer patients; objective response rate (ORR) and disease control rate (DCR) were used as the main outcome indicators, and statistical analysis was performed using RevMan5.3 and State15.3 software. A total of 13 studies were included in this study, including 1057 patients with locally advanced cervical cancer, suggesting that endostar combined with chemoradiotherapy can significantly improve the objective response rate (ORR: odds ratio 3.88, 95% confidence interval 2.77-5.45, P < .00001) and disease control rate (DCR: odds ratio 4.43, 95% confidence interval 2.78-7.04; P < .00001), and there was no significant increase in treatment-related adverse reactions. In this meta-analysis, endostar combined with concurrent chemoradiotherapy significantly improved ORR and DCR in patients with locally advanced cervical cancer without increasing toxicity. However, this study only analyzed the short-term efficacy of endostar, and its influence on overall survival and progression-free survival needs to be further verified in large randomized controlled trials with long-term follow-up.
Sections du résumé
BACKGROUND
BACKGROUND
To evaluate the role and safety of endostar in cervical cancer by comparing the efficacy and adverse reactions of endostar combined with concurrent chemoradiotherapy in patients with locally advanced cervical carcinoma.
METHODS
METHODS
The quality of the included literature was evaluated by searching the database for the comparison of endostar combined with concurrent radiotherapy and chemotherapy in cervical cancer patients; objective response rate (ORR) and disease control rate (DCR) were used as the main outcome indicators, and statistical analysis was performed using RevMan5.3 and State15.3 software.
RESULTS
RESULTS
A total of 13 studies were included in this study, including 1057 patients with locally advanced cervical cancer, suggesting that endostar combined with chemoradiotherapy can significantly improve the objective response rate (ORR: odds ratio 3.88, 95% confidence interval 2.77-5.45, P < .00001) and disease control rate (DCR: odds ratio 4.43, 95% confidence interval 2.78-7.04; P < .00001), and there was no significant increase in treatment-related adverse reactions.
CONCLUSIONS
CONCLUSIONS
In this meta-analysis, endostar combined with concurrent chemoradiotherapy significantly improved ORR and DCR in patients with locally advanced cervical cancer without increasing toxicity. However, this study only analyzed the short-term efficacy of endostar, and its influence on overall survival and progression-free survival needs to be further verified in large randomized controlled trials with long-term follow-up.
Identifiants
pubmed: 36086700
doi: 10.1097/MD.0000000000030170
pii: 00005792-202209090-00028
doi:
Substances chimiques
Endostatins
0
Recombinant Proteins
0
endostar protein
GVG18ZDN65
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e30170Informations de copyright
Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Tornesello ML, Faraonio R, Buonaguro L, et al. The role of microRNAs, long non-coding RNAs, and circular RNAs in cervical cancer. Front Oncol. 2020;10:150.
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.
El-Zein M, Richardson L, Franco EL. Cervical cancer screening of HPV vaccinated populations: cytology, molecular testing, both or none. J Clin Virol. 2016;76(suppl 1):S62–8.
Guo M, Xu J, Du J. Trends in cervical cancer mortality in China from 1989 to 2018: an age-period-cohort study and Joinpoint analysis. BMC Public Health. 2021;21:1329.
Nishio M, To Y, Maehama T, et al. Endogenous YAP1 activation drives immediate onset of cervical carcinoma in situ in mice. Cancer Sci. 2020;111:3576–87.
Kilic F, Cakir C, Yuksel D, et al. Analysis of the prognostic factors determining the oncological outcomes in patients with high-risk early-stage cervical cancer. J Obstet Gynaecol. 2022;42:281–8.
Todo Y, Watari H. Concurrent chemoradiotherapy for cervical cancer: background including evidence-based data, pitfalls of the data, limitation of treatment in certain groups. Chin J Cancer Res. 2016;28:221–7.
Eckert F, Zwirner K, Boeke S, et al. Rationale for combining radiotherapy and immune checkpoint inhibition for patients with hypoxic tumors. Front Immunol. 2019;10:407.
Lee P, Chandel NS, Simon MC. Cellular adaptation to hypoxia through hypoxia inducible factors and beyond. Nat Rev Mol Cell Biol. 2020;21:268–83.
Cervantes-Villagrana RD, Albores-García D, Cervantes-Villagrana AR, et al. Tumor-induced neurogenesis and immune evasion as targets of innovative anti-cancer therapies. Signal Transduct Target Ther. 2020;5:99.
Klein A, Loewenstein A. Therapeutic monoclonal antibodies and fragments: bevacizumab. Dev Ophthalmol. 2016;55:232–45.
Shu Q, Li W, Li H, et al. Vasostatin inhibits VEGF-induced endothelial cell proliferation, tube formation and induces cell apoptosis under oxygen deprivation. Int J Mol Sci. 2014;15:6019–30.
Xu F, Ma Q, Sha H. Optimizing drug delivery for enhancing therapeutic efficacy of recombinant human endostatin in cancer treatment. Crit Rev Ther Drug Carrier Syst. 2007;24:445–92.
Liu X, Nie W, Xie Q, et al. Endostatin reverses immunosuppression of the tumor microenvironment in lung carcinoma. Oncol Lett. 2018;15:1874–80.
Shu H, Dong Y, Xu Z, et al. The efficacy and safety of continuous intravenous endostar treatment combined with concurrent chemoradiotherapy in patients with locally advanced cervical squamous cell carcinoma: a randomized controlled trial. Front Oncol. 2021;11:723193.
Lu H, Wu Y, Liu X, et al. Endostar, an antiangiogenesis inhibitor, combined with chemoradiotherapy for locally advanced cervical cancer. Oncol Res. 2022;28:929–44.
Chen J, Fu H. The efficacy of endostar combined with radiotherapy and chemotherapy and its effects on imbalance of CD4+ T cells of advanced cervical cancer patients. Zhongliu Yaoxue Zazhi. 2020;10:709–13.
Dili S, Aisi T, Zhao H, et al. Analysis of the efficacy and safety of concurrent chemoradiotherapy combined with recombinant human endostatin in the treatment of advanced cervical cancer. Zhongguo Yixue Qianyan Zazhi. 2020;12:61–5.
Tang Y. The study of endostar on sensitization of radiotherapy for cervical cancer. Dalian Medical University. 2019.
Xu X, Wen S, Wang H. Clinical study of endostar combined with hyperthermiaand radiochemotherapy for the treatment of advanced cervicalcancers. Xiandai Yangsheng. 2018:39–40.
Fan Y, Yu Z, Cui X, et al. Recombinant human endostar combined with chemoradiotherapy Therapeutic effect analysis of cervical cancer. Zhongguo Yaowu Yu Linchuang. 2017;17:865–68.
Luo J. Effect of recombinant human endostatin in adjuvant treatment of advanced cervical cancer. Shandong Yiyao. 2016;56:72–4.
Liu X, Hou B, Xiaojun S, et al. Endostar degrees with chemoradiation therapy period giant block type cervical cancer clinical curative effect observation. Wujing Houqin Xueyuan Xuebao. 2013;22:178–81.
Ke Q, Zhou S, Du W, et al. Chemoradiation joint human recombinant endostatin treatment for locally advanced cervical cancer efficacy analysis of 52 cases. Shiyong Aizheng Zazhi. 2012;27:373–5.
Zhao J, Dong X, Zhao J, et al. Human recombinant endostatin combined hydroxyurea chemoradiation curative effect observation of treatment of locally advanced cervical cancer. Zhongguo Shiyong Yiyao. 2012;7:65–6.
Zhang Y. Concurrent chemoradiotherapy combined therapy with recombinant human endostatin middle-late analysis of the clinical effect and prognosis of cervical cancer. Shanxi Yiyao Zazhi. 2017;46:1711–4.
Li J. The effect of ondo combined with concurrent radiotherapy and chemotherapy in the treatment of locally advanced cervical cancer and its effect on serum VEGF,SCCA, CYFRA21-1. Shiyong Aizheng Zazhi. 2021;36:1136–9.
Chaudary N, Hill RP, Stulik L, et al. The oral CXCR4 inhibitor X4-136 improves tumor control and reduces toxicity in cervical cancer treated with radiation therapy and concurrent chemotherapy. Int J Radiat Oncol Biol Phys. 2021;110:1317–24.
Gray SL, Hall KE, Powell LL, et al. Tissue oxygen saturation in dogs with acute hemorrhage. J Vet Emerg Crit Care (San Antonio). 2018;28:408–14.
Abou Khouzam R, Brodaczewska K, Filipiak A, et al. Tumor hypoxia regulates immune escape/invasion: influence on angiogenesis and potential impact of hypoxic biomarkers on cancer therapies. Front Immunol. 2021;11:613114.
Shen X, Zhi Q, Wang Y, et al. Hypoxia induces multidrug resistance via enhancement of epidermal growth factor-like domain 7 expression in non-small lung cancer cells. Chemotherapy. 2017;62:172–80.
Korbecki J, Kojder K, Barczak K, et al. Hypoxia alters the expression of CC chemokines and CC chemokine receptors in a tumor-A literature review. Int J Mol Sci . 2020;21:5647.
Yart L, Bastida-Ruiz D, Allard M, et al. Linking unfolded protein response to ovarian cancer cell fusion. BMC Cancer. 2022;22:622.
Viallard C, Larrivée B. Tumor angiogenesis and vascular normalization: alternative therapeutic targets. Angiogenesis. 2017;20:409–26.
Hang X, Zhao L, Wu B, et al. BCL-2 isoform β promotes angiogenesis by TRiC-mediated upregulation of VEGF-A in lymphoma. Oncogene. 2022;41:3655–63.
Zhang G, Jin G, Nie X, et al. Enhanced antitumor efficacy of an oncolytic herpes simplex virus expressing an endostatin-angiostatin fusion gene in human glioblastoma stem cell xenografts. PLoS One. 2014;9:e95872.
Jia Y, Liu M, Cao L, et al. Recombinant human endostatin, Endostar, enhances the effects of chemo-radiotherapy in a mouse cervical cancer xenograft model. Eur J Gynaecol Oncol. 2011;32:316–24.
Lin K, Ye P, Liu J, et al. Endostar inhibits hypoxia-induced cell proliferation and migration via the hypoxia-inducible factor-1α/vascular endothelial growth factor pathway in vitro. Mol Med Rep. 2015;11:3780–5.
Li Y, Tian Y, Jin F, et al. A phase II multicenter randomized controlled trial to compare standard chemoradiation with or without recombinant human endostatin injection (Endostar) therapy for the treatment of locally advanced nasopharyngeal carcinoma: long-term outcomes update. Curr Probl Cancer. 2020;44:100492.
Zhang X. Endostar combined GP scheme used for patients with advanced non-small cell lung cancer clinical treatment effect. Zhongguo Baojian Yingyang. 2020;30:78.